Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers

Liu, Youqiang; Cui, Haijing; Zhang, Futong; Zhao, Liyan; Liu, Yibing; Meng, Qingju

doi:10.1080/10717544.2022.2027573

Cited by 37 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanostructured lipid carriers (NLCs) are important from a therapeutic point of view due to their multiple implementations in addressing the most aggressive variants of cancer (carcinoma and melanoma), combination therapy, and different modes of delivery including oral. − For example, in gastric carcinoma, etoposide-loaded nanostructured lipid carriers have shown impressive entrapment efficiency along with enhanced antitumor effect against SGC7901 cells as compared to the free drug . Furthermore, codelivery of multiple agents can also be achieved by lipid carriers with the advantage of the synergistic effect of the drugs (such as DOX and lapachone), one of the prominent examples of which is the curcumin and etoposide delivery system, with a drug loading quantity of >80% for each drug .…”

Section: Lipid-based Ndds In Cancer Therapymentioning

confidence: 99%

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Khan

Hossain

et al. 2022

ACS Appl. Bio Mater.

209

View full text Add to dashboard Cite

Traditional treatment approaches for cancer involve intravenous chemotherapy or other forms of drug delivery. These therapeutic measures suffer from several limitations such as nonspecific targeting, poor biodistribution, and buildup of drug resistances. However, significant technological advancements have been made in terms of superior modes of drug delivery over the last few decades. Technical capability in analyzing the molecular mechanisms of tumor biology, nanotechnologyparticularly the development of biocompatible nanoparticles, surface modification techniques, microelectronics, and material scienceshas increased. As a result, a significant number of nanostructured carriers that can deliver drugs to specific cancerous sites with high efficiency have been developed. This particular maneuver that enables the introduction of a therapeutic nanostructured substance in the body by controlling the rate, time, and place is defined as the nanostructured drug delivery system (NDDS). Because of their versatility and ability to incorporate features such as specific targeting, water solubility, stability, biocompatibility, degradability, and ability to reverse drug resistance, they have attracted the interest of the scientific community, in general, and nanotechnologists as well as biomedical scientists. To keep pace with the rapid advancement of nanotechnology, specific technical aspects of the recent NDDSs and their prospects need to be reported coherently. To address these ongoing issues, this review article provides an overview of different NDDSs such as lipids, polymers, and inorganic nanoparticles. In addition, this review also reports the challenges of current NDDSs and points out the prospective research directions of these nanocarriers. From our focused review, we conclude that still now the most advanced and potent field of application for NDDSs is lipid-based, while other significantly potential fields include polymer-based and inorganic NDDSs. However, despite the promises, challenges remain in practical implementations of such NDDSs in terms of dosage and stability, and caution should be exercised regarding biocompatibility of materials. Considering these aspects objectively, this review on NDDSs will be particularly of interest for small-to-large scale industrial researchers and academicians with expertise in drug delivery, cancer research, and nanotechnology.

show abstract

Section: Lipid-based Ndds In Cancer Therapymentioning

confidence: 99%

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Khan

Hossain

et al. 2022

ACS Appl. Bio Mater.

209

View full text Add to dashboard Cite

show abstract

“…Targeted cancer therapies have enabled improved cancer outcomes with better adverse effect profiles [ 45 ]. Conatumumab is a proapoptotic death receptor 5 agonist antibody that has been trialled in multiple cancers [ 46 , 47 ]. It acts by targeting TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) R2, which is currently a focus on investigation [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients

Zhuang

Zhou

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Background. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) leads to significant morbidity. Other coadministered drugs may modulate the risk for BRONJ. The present study aimed to leverage bioinformatic data mining to identify drugs that potentially modulate the risk of BRONJ in cancer. Methods. A GEO gene expression dataset of peripheral blood mononuclear cells related to BRONJ in multiple myeloma patients was downloaded, and differentially expressed genes (DEGs) in patients with BRONJ versus those without BRONJ were identified. A protein-protein interaction network of the DEGs was constructed using experimentally validated interactions in the STRING database. Overrepresented Gene Ontology (GO) molecular function terms and KEGG pathways in the network were analysed. Network topology was determined, and ‘hub genes’ with degree ≥2 in the network were identified. Known drug targets of the hub genes were mined from the ‘drug gene interaction database’ (DGIdb) and labelled as candidate drugs affecting the risk of BRONJ. Results. 751 annotated DEGs ( log FC ≥ 1.5 , p < 0.05 ) were obtained from the microarray gene expression dataset GSE7116. A PPI network with 633 nodes and 168 edges was constructed. Data mining for drugs interacting with 49 gene nodes was performed. 37 drug interactions were found for 9 of the hub genes including TBP, TAF1, PPP2CA, PRPF31, CASP8, UQCRB, ACTR2, CFLAR, and FAS. Interactions were found for several established and novel anticancer chemotherapeutic, kinase inhibitor, caspase inhibitor, antiangiogenic, and immunomodulatory agents. Aspirin, metformin, atrovastatin, thrombin, androgen and antiandrogen drugs, progesterone, Vitamin D, and Ginsengoside 20(S)-Protopanaxadiol were also documented. Conclusions. A bioinformatic data mining strategy identified several anticancer, immunomodulator, and other candidate drugs that may affect the risk of BRONJ in cancer patients.

show abstract

“…Upon intravenous (i.v.) injection every three days into mice bearing colorectal cancer xenografts, Liu et al [ 48 ] verified a reduction of tumor growth without systemic toxicity through the decoration of NLC co-delivering irinotecan prodrug (2 mg/kg) and quercetin (2 mg/kg) with conatumumab/AMG 655 (anti-DR5 mAb).…”

Section: Antibody-functionalized Lipid Nanoparticles For Anticancer D...mentioning

confidence: 99%

Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy

et al. 2023

View full text Add to dashboard Cite

Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles—solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid–polymer hybrid nanoparticles—have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current “state-of-the-art” in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.

show abstract

Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers

Cited by 37 publications

References 46 publications

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review

Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients

Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy

Contact Info

Product

Resources

About